

Product Datasheet

BICD1 Antibody - BSA Free

NBP1-78735

Unit Size: 100 ul

Store at 4C. Do not freeze.

www.novusbio.com



technical@novusbio.com

Publications: 3

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP1-78735

Updated 9/9/2025 v.20.1

Earn rewards for product
reviews and publications.

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NBP1-78735



NBP1-78735

BICD1 Antibody - BSA Free


Product Information	
Unit Size	100 ul
Concentration	1.0 mg/ml
Storage	Store at 4C. Do not freeze.
Clonality	Polyclonal
Preservative	0.09% Sodium Azide
Isotype	IgG
Purity	Immunogen affinity purified
Buffer	Tris-Citrate/Phosphate (pH 7.0 - 8.0)

Product Description	
Description	Novus Biologicals Rabbit BICD1 Antibody - BSA Free (NBP1-78735) is a polyclonal antibody validated for use in WB and IP. Anti-BICD1 Antibody: Cited in 3 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Rabbit
Gene ID	636
Gene Symbol	BICD1
Species	Human
Immunogen	The immunogen for this product maps to a region between residue 550 and 600 of human Bicaudal D Homolog 1 using the numbering given in entry NP_001705.2 (GeneID 636).


Product Application Details	
Applications	Western Blot, Immunoprecipitation, Knockdown Validated
Recommended Dilutions	Western Blot 1:2000-1:10000, Immunoprecipitation 2 - 10 µg/mg lysate, Knockdown Validated

Images


Western Blot: BICD1 Antibody [NBP1-78735] - Whole cell lysate from Jurkat (15 and 50 mcg for WB; 1 mg for IP, 20% of IP loaded), 293T (T; 50 mcg) and HeLa (H; 50 mcg) cells. Affinity purified rabbit anti-BICD1 antibody used for WB at 0.1 mcg/ml (A) and 1 mcg/ml (B) and used for IP at 6 mcg/mg lysate. BICD1 was also immunoprecipitated by rabbit anti-BICD1 antibody NBP1-78734 which recognizes an upstream epitope.




Western Blot: BICD1 Antibody [NBP1-78735] - Effect of hypoxia on the interaction between HIF-1 alpha and BICD1. Cells were pretreated with MG132 (1 μ M) for 30 min prior to hypoxia treatment for 24 h. Co-immunoprecipitation of HIF-1 alpha with IgG and BICD1 were shown in left panel. Total protein expressions in lysate were shown in right panel. n = 3. Image collected and cropped by CiteAb from the following publication (<https://www.nature.com/articles/s41418-018-0241-1>), licensed under a CC-BY license.




Western Blot: BICD1 Antibody [NBP1-78735] - Role of BICD1 in UCB-MSCs survival under hypoxia. a, b The UCB-MSCs were transfected with BICD1 or NT siRNA for 24 h prior to hypoxia treatment. a Cells were exposed to various durations of hypoxia (0–72 h). Cell viability of UCB-MSCs was measured by WST-1 cell viability assay. n = 8. b Cells were incubated in normoxia or hypoxia conditions for 72 h. Representative images of experimental groups at 0, 24, 48, & 72 h of normoxia or hypoxia incubation are presented. Red-marked cells in representative images indicate PI-positive cells. n = 4. Scale bars are 50 μ m (Magnification, \times 200). c BICD1 or NT siRNA-transfected cells were incubated in hypoxia for 24 h. Cleaved caspase-9, cleaved caspase-3, & β -Actin protein expressions were detected by western blot analysis. n = 4. d Cells were transfected with BICD1 or NT siRNA for 24 h prior to hypoxia treatment for 48 h. The percentages of apoptotic cells were analyzed by Annexin V/PI analysis, measured by flowcytometer. Annexin V-positive cells were considered as apoptotic cells. n = 4. Quantitative data are presented as a mean \pm S.E.M. All blot images are representative. *p < 0.05 vs. normoxia control with NT siRNA transfection, #p < 0.05 vs. hypoxia with NT siRNA transfection. e The UCB-MSCs were transfected with pcDNA3.1/BICD1-cEGFP vector, pcDNA3.1/cEGFP vector, HIF1A siRNA or NT siRNA for 24 h prior to hypoxia treatment for 72 h. Cell viability data are presented as a mean \pm S.E.M. n = 5. *p < 0.05 vs. normoxia control with pcDNA3.1/cEGFP vector & NT siRNA cotransfection, #p < 0.05 vs. hypoxia control with pcDNA3.1/cEGFP vector & NT siRNA cotransfection, @p < 0.05 vs. hypoxia control with pcDNA3.1/BICD1-cEGFP vector & NT siRNA cotransfection. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/30464225>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




Western Blot: BICD1 Antibody [NBP1-78735] - Effect of hypoxia on the interaction between HIF1 α & BICD1. a Co-immunoprecipitation of HIF1 α , Dynein IC, Importin α 3, RanBP2 w/ IgG & BICD1 antibodies shown in left panel. Total protein expressions in lysate shown in right panel. n = 3. b Cells immunostained w/ HIF1 α & BICD1-specific antibodies. Scale bars are 8 μ m (Magnification, \times 1,000). White arrow heads indicate co-localization of HIF1 α w/ BICD1. c Interaction between HIF1 α & BICD1 (HIF1 α /BICD1, red) analyzed by PLA. Scale bars are 8 μ m (Magnification, \times 1,000). n = 6. *p < 0.05 vs. normoxia control. d-f Cells pretreated w/ MG132 (1 μ M) for 30 min prior to hypoxia treatment for 24 h. d Co-immunoprecipitation of HIF1 α w/ IgG & BICD1 shown in left panel. Total protein expressions in lysate shown in right panel. n = 3. e Cells immunostained w/ HIF1 α & BICD1-specific antibodies. White arrow heads indicate co-localization of HIF1 α w/ BICD1 in MG132-pretreated UCB-MSCs. Scale bars are 8 μ m (Magnification, \times 1,000). n = 5. f HIF1 activity measured by dual luciferase reporter assay. n = 6. *p < 0.05 vs. normoxia control w/ MG132 pretreatment. g, h Cells transfected w/ BICD1 or NT siRNA for 24 h prior to hypoxia treatment for 24 h. g Co-immunoprecipitation of Dynein IC w/ IgG & HIF1 α antibodies shown in left panel. Total protein expressions in lysate shown in right panel. n = 3. h Interaction between HIF1 α & Dynein IC (HIF1 α /Dynein IC, red) analyzed by PLA. Scale bars are 8 μ m (Magnification, \times 1,000). Quantitative data are presented as a mean \pm S.E.M. All blots & immunofluorescence images are representative. *p < 0.05 vs. normoxia control w/ NT siRNA transfection, #p < 0.05 vs. hypoxia w/ NT siRNA transfection Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/30464225>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Western Blot: BICD1 Antibody [NBP1-78735] - Effect of hypoxia on the interaction between HIF1 α & BICD1. a Co-immunoprecipitation of HIF1 α , Dynein IC, Importin α 3, RanBP2 w/ IgG & BICD1 antibodies shown in left panel. Total protein expressions in lysate shown in right panel. n = 3. b Cells immunostained w/ HIF1 α & BICD1-specific antibodies. Scale bars are 8 μ m (Magnification, \times 1,000). White arrow heads indicate co-localization of HIF1 α w/ BICD1. c Interaction between HIF1 α & BICD1 (HIF1 α /BICD1, red) analyzed by PLA. Scale bars are 8 μ m (Magnification, \times 1,000). n = 6. *p < 0.05 vs. normoxia control. d-f Cells pretreated w/ MG132 (1 μ M) for 30 min prior to hypoxia treatment for 24 h. d Co-immunoprecipitation of HIF1 α w/ IgG & BICD1 shown in left panel. Total protein expressions in lysate shown in right panel. n = 3. e Cells immunostained w/ HIF1 α & BICD1-specific antibodies. White arrow heads indicate co-localization of HIF1 α w/ BICD1 in MG132-pretreated UCB-MSCs. Scale bars are 8 μ m (Magnification, \times 1,000). n = 5. f HIF1 activity measured by dual luciferase reporter assay. n = 6. *p < 0.05 vs. normoxia control w/ MG132 pretreatment. g, h Cells transfected w/ BICD1 or NT siRNA for 24 h prior to hypoxia treatment for 24 h. g Co-immunoprecipitation of Dynein IC w/ IgG & HIF1 α antibodies shown in left panel. Total protein expressions in lysate shown in right panel. n = 3. h Interaction between HIF1 α & Dynein IC (HIF1 α /Dynein IC, red) analyzed by PLA. Scale bars are 8 μ m (Magnification, \times 1,000). Quantitative data are presented as a mean \pm S.E.M. All blots & immunofluorescence images are representative. *p < 0.05 vs. normoxia control w/ NT siRNA transfection, #p < 0.05 vs. hypoxia w/ NT siRNA transfection Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/30464225>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Western Blot: BICD1 Antibody [NBP1-78735] - Involvement of Akt/GSK3 β pathway in BICD1-mediated HIF1 α nuclear translocation. a–e The UCB-MSCs were transfected with GSK3 β or NT siRNA for 24 h prior to hypoxia treatment for 24 h. a Co-immunoprecipitation of HIF1 α & Dynein IC with IgG & BICD1 antibodies were shown in left panel. Total protein expressions in lysate were shown in right panel. n = 3. b Interaction between HIF1 α & BICD1 (HIF1 α /BICD1, red) was analyzed by PLA assay. Scale bars are 8 μ m (Magnification, \times 1,000). n = 5. c HIF1 α , Lamin A/C, & α -Tubulin in cytosolic & nuclear fractionized samples were detected by western blot. n = 4. d Cells were immunostained with HIF1 α -specific antibody. Scale bars are 8 μ m (Magnification, \times 1,000). n = 4. e HIF1 activities in NT or GSK3 β siRNA-transfected cells were analyzed by dual luciferase reporter assay. n = 6. Quantitative data are presented as a mean \pm S.E.M. All blots & immunofluorescence images are representative. *p < 0.05 vs. normoxia control with NT siRNA transfection, #p < 0.05 vs. hypoxia with NT siRNA transfection Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/30464225>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Jiang Y, Yao B, Chen T et al. BICD1 functions as a prognostic biomarker and promotes hepatocellular carcinoma progression Pathol. Res. Pract. 2020-02-12 [PMID: 32088084] (WB, Human)

Lee HJ, Jung YH, Choi GE et al. O-cyclic phytosphingosine-1-phosphate stimulates HIF1 alpha-dependent glycolytic reprogramming to enhance the therapeutic potential of mesenchymal stem cells Cell Death Dis 2019-08-05 [PMID: 31383843] (WB)

Lee HJ, Jung YH, Oh JY et al. BICD1 mediates HIF1a nuclear translocation in mesenchymal stem cells during hypoxia adaptation. Cell Death Differ. 2018-11-21 [PMID: 30464225] (WB, Human)



Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NBP1-78735

HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control
NBP1-76922PEP	BICD1 Antibody Blocking Peptide

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP1-78735

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

